IntroductionInflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), is a chronic, relapsing, and incurable disease with low mortality. As IBD predominantly affects young adults and carries a lifetime morbidity and low mortality, the disease places a considerable burden on public health and health‐care resources. Previous studies have demonstrated that the direct and indirect costs of IBD are considerably high. In two large population‐based studies from North America, the total IBD‐associated health‐care costs were estimated as $2.8 billion in Canada and $6.3 billion in the USA (US) per year. Additionally, the cost profile of IBD care has changed over time. Because highly effective biological therapies such as anti‐tumor necrosis factor (TNF) agents have been developed, the health‐care cost of IBD has shifted from hospitalization and surgery to anti‐TNF therapy in Europe.The incidence of IBD in Asia has risen steadily over the past few decades. A nationwide population‐based study of Korea showed that the mean annual incidence of UC was 4.6 per 100 000 and that of CD was 6.2 per 100 000 from 2006 to 2012. Cumulative epidemiologic data from Korea have showed that the incidence of IBD has increased about 10‐fold over two decades in Korea.
Journal of Gastroenterology and Hepatology – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.
All for just $49/month
Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.
Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.
It’s easy to organize your research with our built-in tools.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera